指南与共识呼吸衰竭与机械通气

免疫实践咨询委员会关于≥18岁成人使用Moderna COVID-19疫苗的建议及mRNA COVID-19疫苗基础免疫系列延长接种间隔的考量——美国,2022年2月

The Advisory Committee on Immunization Practices' Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines - United States, February 2022.
指南 / 共识 · MMWR Morb Mortal Wkly Rep · 2022-03-18
一句话结论ACIP于2022年2月4日将Moderna COVID-19疫苗在≥18岁人群中的使用建议由临时建议改为标准建议,并指出8周间隔对部分青少年和成人可能最优。

mRNA-1273(Moderna)COVID-19疫苗为脂质纳米颗粒包裹的核苷修饰mRNA疫苗,编码SARS-CoV-2稳定融合前刺突糖蛋白。2020年12月获FDA紧急使用授权,ACIP发布≥18岁人群临时建议。2020年12月19日至2022年1月30日美国约接种2.04亿剂,基础系列为2剂肌肉注射,每剂100 μg(0.5 mL),间隔4周。2022年1月31日FDA批准该疫苗生物制品许可申请。2022年2月4日ACIP基于证据至推荐框架(EtR)和GRADE方法,结合临床试验随访、真实世界疫苗有效性研究和上市后安全性监测,将临时建议修改为≥18岁人群使用完全获批Moderna COVID-19疫苗的标准建议;CDC指南指出8周间隔对部分青少年和成人可能最优。

要点

  • ACIP于2022年2月4日将Moderna COVID-19疫苗在≥18岁人群中的使用建议由临时建议改为标准建议。
  • 基础系列为2剂肌肉注射,每剂100 μg(0.5 mL),间隔4周。
  • 2020年12月19日至2022年1月30日美国约接种2.04亿剂Moderna COVID-19疫苗。
  • CDC指南指出,8周间隔对部分青少年和成人可能最优。
  • ACIP基于EtR框架和GRADE方法,结合临床试验随访、真实世界疫苗有效性研究和上市后安全性监测,认为预防有症状和无症状SARS-CoV-2感染、住院和死亡的获益大于疫苗相关风险。

适用人群与场景

  • ≥18岁成人。
  • 部分青少年和成人可考虑8周接种间隔(CDC指南)。

处置流程与药物剂量

  • 基础系列为2剂肌肉注射,每剂100 μg(0.5 mL),间隔4周。
  • CDC指南指出,8周间隔对部分青少年和成人可能最优。

研究设计与关键结果

  • 2020年12月19日至2022年1月30日,美国约接种2.04亿剂Moderna COVID-19疫苗。
  • 2022年1月31日,FDA批准Moderna COVID-19疫苗(Spikevax,ModernaTX, Inc.)用于≥18岁人群的生物制品许可申请。
  • 2022年2月4日,ACIP将临时建议修改为≥18岁人群使用完全获批Moderna COVID-19疫苗的标准建议。

证据类型、等级与局限

  • 证据类型:指南(ACIP建议)。
  • 证据分级方法:证据至推荐(EtR)框架,采用推荐分级的评估、制定与评价(GRADE)方法对证据质量进行分级。
  • ACIP考虑的额外信息包括:临床试验额外随访时间、真实世界疫苗有效性研究、上市后疫苗安全性监测,以及mRNA疫苗在真实世界中首剂间隔8周与临床试验原间隔(BNT162b2为3周,Moderna为4周)的有效性和安全性比较。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • ACIP推荐≥18岁成人使用完全获批的Moderna COVID-19疫苗(标准建议)。
  • CDC指南指出,8周间隔对部分青少年和成人可能最优。

指南或共识出处

  • ACIP建议,2022年2月4日。
  • CDC指南。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

The mRNA-1273 (Moderna) COVID-19 vaccine is a lipid nanoparticle-encapsulated, nucleoside-modified mRNA vaccine encoding the stabilized prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. During December 2020, the vaccine was granted Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA), and the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use among persons aged ≥18 years (1), which was adopted by CDC. During December 19, 2020-January 30, 2022, approximately 204 million doses of Moderna COVID-19 vaccine were administered in the United States (2) as a primary series of 2 intramuscular doses (100 μg [0.5 mL] each) 4 weeks apart. On January 31, 2022, FDA approved a Biologics License Application (BLA) for use of the Moderna COVID-19 vaccine (Spikevax, ModernaTX, Inc.) in persons aged ≥18 years (3). On February 4, 2022, the ACIP COVID-19 Vaccines Work Group conclusions regarding recommendations for the use of the Moderna COVID-19 vaccine were presented to ACIP at a public meeting. The Work Group's deliberations were based on the Evidence to Recommendation (EtR) Framework,* which incorporates the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach† to rank evidence quality. In addition to initial clinical trial data, ACIP considered new information gathered in the 12 months since issuance of the interim recommendations, including additional follow-up time in the clinical trial, real-world vaccine effectiveness studies, and postauthorization vaccine safety monitoring. ACIP also considered comparisons of mRNA vaccine effectiveness and safety in real-world settings when first doses were administered 8 weeks apart instead of the original intervals used in clinical trials (3 weeks for BNT162b2 [Pfizer-BioNTech] COVID-19 vaccine and 4 weeks for Moderna COVID-19 vaccine). Based on this evidence, CDC has provided guidance that an 8-week interval might be optimal for some adolescents and adults. The additional information gathered since the issuance of the interim recommendations increased certainty that the benefits of preventing symptomatic and asymptomatic SARS-CoV-2 infection, hospitalization, and death outweigh vaccine-associated risks of the Moderna COVID-19 vaccine. On February 4, 2022, ACIP modified its interim recommendation to a standard recommendation§ for use of the fully licensed Moderna COVID-19 vaccine in persons aged ≥18 years.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

参考来源

  1. Wallace M, Moulia D, Blain AE, et al. The Advisory Committee on Immunization Practices' Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines - United States, February 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35298454. doi:10.15585/mmwr.mm7111a4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。